Literature DB >> 12417521

Identification of the coding sequences responsible for Tsc2-mediated tumor suppression using a transgenic rat system.

Shuji Momose1, Toshiyuki Kobayashi, Hiroaki Mitani, Masumi Hirabayashi, Kazumi Ito, Masatsugu Ueda, Yo-ichi Nabeshima, Okio Hino.   

Abstract

Hereditary renal carcinomas in the Eker rat are caused by germline retrotransposon insertion in the tuberous sclerosis-2 (Tsc2) gene. We established previously a transgenic Eker rat model into which was introduced a wild-type Tsc2 gene. The embryonic lethality of mutant homozygotes and renal carcinogenesis of heterozygotes were completely suppressed by this transgene (Tg). The function of the Tsc2 product (tuberin) is not fully understood, although several findings have been obtained mainly in vitro. Therefore, to elucidate the functional domains of Tsc2 in vivo, we generated transgenic Eker rats carrying deletion mutants of the Tsc2 gene. A Tg coding for the C-terminal region (amino acids 1425-1755) suppressed renal carcinogenesis in the Eker rat and interestingly the degree of this suppression correlated with the level of expression of the Tg. Notably, the product of this Tg lacks the ability to bind to the Tsc1 product (hamartin). Surprisingly, while a Tg lacking the C-terminus of tuberin (amino acids 1-1755) completely suppressed renal carcinogenesis, it partially rescued homozygous mutants from embryonic lethality. In conclusion, we have determined the minimal region of tuberin necessary for tumor suppression but the suppressive effect was quantitative. Tuberin could function as a tumor suppressor without binding to hamartin. The requirement of the functional domain(s) of tuberin might differ for prevention of embryonic lethality and for suppression of renal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417521     DOI: 10.1093/hmg/11.24.2997

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  7 in total

1.  Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.

Authors:  Ken Inoki; Yong Li; Tian Xu; Kun-Liang Guan
Journal:  Genes Dev       Date:  2003-07-17       Impact factor: 11.361

2.  Rho-associated kinase connects a cell cycle-controlling anchorage signal to the mammalian target of rapamycin pathway.

Authors:  Jung-ha Park; Shiho Arakawa-Takeuchi; Shigeki Jinno; Hiroto Okayama
Journal:  J Biol Chem       Date:  2011-05-11       Impact factor: 5.157

3.  Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.

Authors:  Elena A Goncharova; Dmitriy A Goncharov; Matthew Spaits; Daniel J Noonan; Ekaterina Talovskaya; Andrew Eszterhas; Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2006-01-19       Impact factor: 6.914

4.  Update on the cytogenetics and molecular genetics of chordoma.

Authors:  Lidia Larizza; Pietro Mortini; Paola Riva
Journal:  Hered Cancer Clin Pract       Date:  2005-02-15       Impact factor: 2.857

Review 5.  Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.

Authors:  Okio Hino; Toshiyuki Kobayashi
Journal:  Cancer Sci       Date:  2017-01-23       Impact factor: 6.716

6.  Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin.

Authors:  Pike-See Cheah; Shilpa Prabhakar; David Yellen; Roberta L Beauchamp; Xuan Zhang; Shingo Kasamatsu; Roderick T Bronson; Elizabeth A Thiele; David J Kwiatkowski; Anat Stemmer-Rachamimov; Bence György; King-Hwa Ling; Masao Kaneki; Bakhos A Tannous; Vijaya Ramesh; Casey A Maguire; Xandra O Breakefield
Journal:  Sci Adv       Date:  2021-01-08       Impact factor: 14.136

7.  Transgenic expression of the N525S-tuberin variant in Tsc2 mutant (Eker) rats causes dominant embryonic lethality.

Authors:  Masatoshi Shiono; Toshiyuki Kobayashi; Riichi Takahashi; Masatsugu Ueda; Chikashi Ishioka; Okio Hino
Journal:  Sci Rep       Date:  2014-08-04       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.